Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

Infective Endocarditis After TAVR Linked to Diabetes, Residual Aortic Regurgitation in Large Registry

Yael L. Maxwell

September 14, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

L.A. McKeown

May 26, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

News Daily News

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

August 27, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Daily News

‘All-Comers’ Study Shows Survival Benefit of Complete Revascularization in Patients With, Without Diabetes

Caitlin E. Cox

May 08, 2015

News Daily News

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

May 07, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Conference News AHA 2014

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

November 16, 2014

News Daily News

Hybrid Revascularization a Promising Option for Diabetic Patients

L.A. McKeown

July 24, 2014

News Daily News

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

L.A. McKeown

April 11, 2014

Advertisement

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Infective Endocarditis After TAVR Linked to Diabetes, Residual Aortic Regurgitation in Large Registry

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

‘All-Comers’ Study Shows Survival Benefit of Complete Revascularization in Patients With, Without Diabetes

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

Hybrid Revascularization a Promising Option for Diabetic Patients

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content